46. Malignant rheumatoid arthritis Clinical trials / Disease details


Clinical trials : 4,356 Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-004131-84-NL
(EUCTR)
14/02/202208/09/2021Comparing the effectiveness of tofacitinib extended release (XR) chronotherapy, morning versus evening dosing, in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients from a patient’s, clinical as well as a translational point of view.Chronotherapy in Inflammatory Arthritis (ChronIA trial): a crossover randomized controlled trial comparing the effectiveness of morning and evening dosing of tofacitinib extended-release - ChronIA trial Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteria
MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 21.0;Level: LLT;Classification code 10037160;Term: Psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Xeljanz XR
Product Name: Tofacitinib XR
Product Code: EMEA/H/C/004214
Erasmus Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
84Phase 4Netherlands
2NCT04876781
(ClinicalTrials.gov)
January 12, 202220/4/2021Korean Post-marketing Surveillance for Xeljanz XRKorean Post-marketing Surveillance for Xeljanz XR (Registered)Active Moderate to Severe Rheumatoid Arthritis;Active Ankylosing SpondylitisDrug: Tofacitinib XRPfizerNULLRecruiting18 YearsN/AAll200Korea, Republic of